TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12437253

Group type: EXPERIMENTAL
Intervention: G-100 (<= 100 mL/d, n = 44)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: G-150 (<= 150 mL/d, n = 58)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: G-200 (<= 200 mL/d, n = 37)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: G-val (prospective validation group, n = 91)
Number of subjects: 139
Study: 10344212

Group type: EXPERIMENTAL
Intervention: Finasteride (F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of finasteride plus terazosin (C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terazosin (T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 7531900

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d) for 12 months
Number of subjects: 23
Study: 1682247

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg body weight)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg/kg body weight)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both Vecuronium and Pancuronium
Number of subjects: 50
Study: 7159500

Group type: EXPERIMENTAL
Intervention: Guar (15.6 g/day) + Bezafibrate (600 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bezafibrate (600 mg/day) alone
Number of subjects: 12
Study: 30536182

Group type: EXPERIMENTAL
Intervention: Metformin (M) 2000 mg/day plus NPLD 60 mg/m2 + cyclophosphamide 600 mg/m2 × 8 cycles Q21 days (arm A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Chemotherapy alone (NPLD/C) (arm B)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Metformin (M) in patients with HOMA index < 2.5
Number of subjects: 122

Group type: COMPARATOR
Intervention: Chemotherapy alone in patients with HOMA index ≥ 2.5
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Metformin (M) plus chemotherapy (arm A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Chemotherapy alone (arm B)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Metformin (M) induced diarrhea (G2)
Number of subjects: 122
Study: 27907817

Group type: EXPERIMENTAL
Intervention: Featback (fully automated Internet-based intervention)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Featback with low‐intensity (weekly) therapist support
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Featback with high‐intensity (three times a week) therapist support
Number of subjects: 273

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 273
Study: 26086190

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 66
Study: 24848974

Group type: EXPERIMENTAL
Intervention: 12 g/d Soluble maize fibre (SCF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0 g/d Soluble maize fibre (Control treatment)
Number of subjects: 24
Study: 22579053

Group type: EXPERIMENTAL
Intervention: Dietary intervention with physical activity (n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dietary intervention without physical activity (n=45)
Number of subjects: 90
Study: 18394931

Group type: EXPERIMENTAL
Intervention: Gliclazide treatment in Type 2 diabetic patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls (no gliclazide treatment)
Number of subjects: 14
Study: 17868472

Group type: EXPERIMENTAL
Intervention: sirolimus (Rapamune)
Number of subjects: 0
Study: 15817859

Group type: EXPERIMENTAL
Intervention: Selenium as selenomethionine (37 mug Se/d)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Selenium as selenite (66 mug Se/d)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Selenium as selenomethionine and selenite (highest doses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Selenium as selenomethionine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Recommended dietary allowance of selenium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Selenium as selenite
Number of subjects: 120
Study: 12219859

Group type: EXPERIMENTAL
Intervention: Subtle stereotype activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blatant stereotype activation
Number of subjects: 0
Study: 10597397

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid preceded by pantoprazole, 40 mg (P-PCM)
Number of subjects: 107

Group type: COMPARATOR
Intervention: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid followed by pantoprazole, 40 mg (PCM-P)
Number of subjects: 107
Study: 7489182

Group type: EXPERIMENTAL
Intervention: Lexipafant 60 mg intravenously for 3 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 83
Study: 2201157

Group type: EXPERIMENTAL
Intervention: alpha 2‐interferon administered until day 7 of jaundice
Number of subjects: 90

Group type: COMPARATOR
Intervention: common therapy (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: alpha 2‐interferon administered after day 6 of jaundice
Number of subjects: 90
Study: 7362427

Group type: EXPERIMENTAL
Intervention: Community care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 0
Study: 31802405

Group type: EXPERIMENTAL
Intervention: Wii fit game training (40-min sessions, 'Soccer Heading' for first 4 weeks, 'Table Tilt' for last 4 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Wii fit game training
Number of subjects: 64
Study: 31526525

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (LKM)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mindfulness meditation (MM)
Number of subjects: 125
Study: 28125979

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: ETT
Number of subjects: 40
Study: 26061039

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Phenol-Enriched Virgin Olive Oil (FVOO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Phenol-Enriched Virgin Olive Oil with Thyme (FVOOT)
Number of subjects: 33
Study: 23134234

Group type: COMPARATOR
Intervention: CHO trial (8% carbohydrate beverage)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO-P trial (6% carbohydrate plus 2% whey protein beverage)
Number of subjects: 9
Study: 21884533

Group type: EXPERIMENTAL
Intervention: 20 U/kg C1‐INH concentrate (Berinert®)
Number of subjects: 57
Study: 19706737

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 224
Study: 27936526

Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac + 3% menthol gel (administered via tube or roll-on device, 4 g applied 4 times daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac sodium gel (Voltaren Gel, 4 g applied 4 times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral diclofenac sodium tablets (50 mg, 3 times daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac + 3% menthol gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Voltaren Gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 18
Study: 14516806

Group type: EXPERIMENTAL
Intervention: Automated test using Landolt rings
Number of subjects: 206

Group type: COMPARATOR
Intervention: ETDRS chart testing
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Automated test
Number of subjects: 206

Group type: COMPARATOR
Intervention: ETDRS chart
Number of subjects: 206
Study: 10838532

Group type: EXPERIMENTAL
Intervention: Vincristine, doxorubicin, cyclophosphamide, and dactinomycin
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Ifosfamide and etoposide
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control group (vincristine, doxorubicin, cyclophosphamide, and dactinomycin)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Initial surgical resection
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Delayed resection
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Initial surgical resection vs resection after initial chemotherapy
Number of subjects: 393
Study: 9099325

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 59
Study: 8471405

Group type: EXPERIMENTAL
Intervention: Losartan (25 to 200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-3174 (active metabolite of losartan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (multiple dosing for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3861605

Group type: EXPERIMENTAL
Intervention: Enoxacin treatment
Number of subjects: 20
Study: 31880758

Group type: EXPERIMENTAL
Intervention: LPS Adsorber therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham Adsorber therapy
Number of subjects: 32
Study: 30393065

Group type: EXPERIMENTAL
Intervention: Aggressive behavior in children with no sleep problems at baseline
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Model performance in the test sample
Number of subjects: 1045
Study: 27538531

Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 0
Study: 24837264

Group type: EXPERIMENTAL
Intervention: OBSERVANT score (risk scoring system based on 7 baseline clinical variables)
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: OBSERVANT score
Number of subjects: 1256
Study: 23221159

Group type: EXPERIMENTAL
Intervention: Removable partial denture
Number of subjects: 53

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 53
Study: 19911431

Group type: EXPERIMENTAL
Intervention: Manual-plus consultancy group
Number of subjects: 256

Group type: COMPARATOR
Intervention: Manual-alone
Number of subjects: 256
Study: 18219452

Group type: EXPERIMENTAL
Intervention: Trigonella foenum‐graecum L. total saponins (TFGs)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 15730348

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12600907

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10924776

Group type: EXPERIMENTAL
Intervention: Spironolactone (MR antagonist), treated for 8 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo, treated for 8 days
Number of subjects: 9
Study: 8651091

Group type: EXPERIMENTAL
Intervention: Heparin plus urokinase (250 U heparin plus 5,000 U urokinase per minute)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Heparin (250 U heparin per minute)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Heparin plus urokinase
Number of subjects: 280

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 280
Study: 1848421

Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2, day 1, 8, 15) plus three cisplatins (35 mg/m2, day 1, 8, 15)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Vindesine (3 mg/m2, day 1, 8, 15) plus one cisplatin (80 mg/m2, day 1)
Number of subjects: 61
Study: 6439057

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30354633

Group type: EXPERIMENTAL
Intervention: Provisional 1-stent technique
Number of subjects: 529

Group type: COMPARATOR
Intervention: Planned 2-stent technique
Number of subjects: 529
Study: 27556596

Group type: EXPERIMENTAL
Intervention: Nonintubated transareolar ETS with a 2-mm needle endoscope
Number of subjects: 168

Group type: COMPARATOR
Intervention: Intubated transaxillary ETS with a 5-mm thoracoscope
Number of subjects: 168
Study: 24633760

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 1150
Study: 23180064

Group type: EXPERIMENTAL
Intervention: Granisetron and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 0
Study: 20211949

Group type: EXPERIMENTAL
Intervention: Drainage, irrigation, and fibrinolytic therapy (DRIFT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard treatment (tapping off cerebrospinal fluid)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DRIFT
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 77
Study: 19075083

Group type: EXPERIMENTAL
Intervention: Emotional intelligence program (12 weeks)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study: 15760468

Group type: EXPERIMENTAL
Intervention: EMG parameters (RMS and MF) during isometric efforts
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls (n=10)
Number of subjects: 16
Study: 12359681

Group type: EXPERIMENTAL
Intervention: Quality improvement programs for depression (training experts and nurse specialists, access to nurse specialists for medication follow-up, access to psychotherapists)
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual care for depression
Number of subjects: 1356
Study: 10029613

Group type: EXPERIMENTAL
Intervention: Dynamic graciloplasty
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Dynamic gluteoplasty
Number of subjects: 139
Study: 7725384

Group type: EXPERIMENTAL
Intervention: EMIT-d.a.u. class (EC) assay
Number of subjects: 6

Group type: COMPARATOR
Intervention: EMIT-d.a.u. monoclonal amphetamine/methamphetamine (EM) assay
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vicks inhaler (double dosage)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vicks inhaler (recommended dosage)
Number of subjects: 6
Study: 1834242

Group type: EXPERIMENTAL
Intervention: Sufentanil, 25 micrograms/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl, 100 micrograms/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 50
Study: 7032554

Group type: EXPERIMENTAL
Intervention: Verapamil, 120 mg three times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg three times a day
Number of subjects: 0
Study: 30641762

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (50000 IU/week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28526471

Group type: EXPERIMENTAL
Intervention: Hockey-stick stylet (Group HS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: D-blade type stylet (Group DS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CoPilot® videolaryngoscope rigid stylet (Group CS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gum elastic bougie (Group GEB)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No stylet (Group NS)
Number of subjects: 53
Study: 25988317

Group type: EXPERIMENTAL
Intervention: Memantine (5 mg/day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 23146973

Group type: COMPARATOR
Intervention: Group 1 (3 MS criteria)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group 3 (5 MS criteria)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PTX‐3 levels
Number of subjects: 102
Study: 22003345

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 19765309

Group type: EXPERIMENTAL
Intervention: Peer‐led plus Screening Access (PL)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Screening Access only (SCR)
Number of subjects: 1554
Study: 17805214

Group type: EXPERIMENTAL
Intervention: Aripiprazole 9.4+/‐4.2 mg/day
Number of subjects: 19
Study: 15542042

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day and 120 mg/day (pooled)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 11479482

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 40
Study: 10709892

Group type: EXPERIMENTAL
Intervention: Intensive nursing care
Number of subjects: 75
Study: 9104574

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (58% energy, n = 57)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (35% energy, n = 53)
Number of subjects: 110
Study: 1443811

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paracetamol 1 g
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 3888730

Group type: EXPERIMENTAL
Intervention: Limbitrol (25 mg amitriptyline and 10 mg chlordiazepoxide)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Amitriptyline 25 mg
Number of subjects: 434
Study: 30679302

Group type: EXPERIMENTAL
Intervention: Exenatide plus basal insulin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exenatide alone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Basal-bolus insulin regimen
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exenatide and exenatide plus basal
Number of subjects: 150

Group type: COMPARATOR
Intervention: Basal-bolus group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exenatide plus basal, exenatide, and basal-bolus groups
Number of subjects: 150
Study: 29760860

Group type: EXPERIMENTAL
Intervention: Refresher training in scripted communication
Number of subjects: 474

Group type: COMPARATOR
Intervention: No instruction or other intervention related to communication (Control)
Number of subjects: 474
Study: 27617661

Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice a day)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice a day) in patients with BRCAm
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo in patients with BRCAm
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice a day) in patients with BRCA wild-type
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo in patients with BRCA wild-type
Number of subjects: 265
Study: 24890483

Group type: EXPERIMENTAL
Intervention: Habit-based messages
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Food-group messages
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: General healthy eating messages
Number of subjects: 71

Group type: COMPARATOR
Intervention: Delivery method (e-mail vs sms)
Number of subjects: 71
Study: 21959915

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 20151799

Group type: EXPERIMENTAL
Intervention: SRP plus simvastatin (SMV) 1.2 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 60
Study: 18849894

Group type: EXPERIMENTAL
Intervention: Second-generation oral antipsychotics (short-term, 5 days)
Number of subjects: 36
Study: 16009795

Group type: EXPERIMENTAL
Intervention: Intensive therapy (atorvastatin 80 mg/d)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Moderate therapy (pravastatin 40 mg/d)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 615
Study: 11850333

Group type: EXPERIMENTAL
Intervention: Family Information Leaflet (FIL)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard information without FIL
Number of subjects: 175
Study: 9920080

Group type: EXPERIMENTAL
Intervention: Micronized 17beta‐estradiol [0.5 mg/day Estrace (E2)]
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1500 mg/day elemental calcium, given as carbonate plus vitamin D (800 IU/day; Ca+D)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination therapy (Ca+D and E2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 31
Study: 7559274

Group type: EXPERIMENTAL
Intervention: Outpatient intervention program with asthma specialist (allergist/immunologist)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nonintervention group followed by general internist or pediatrician
Number of subjects: 84
Study: 2345485

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (16 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30553760

Group type: EXPERIMENTAL
Intervention: Clinical model (1)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Normalized FDG uptake from Cox-ROI only (2)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Normalized FDG uptake from ANCOVA-ROI only (3)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Clinical variables plus FDG uptake in ANCOVA-ROI (4)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Clinical variables plus FDG uptake from Cox-ROI (5)
Number of subjects: 544
Study: 27416915

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 8 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir/ribavirin for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paritaprevir/r, ombitasvir, dasabuvir for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 12 weeks in treatment experienced patients without cirrhosis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paritaprevir/r, ombitasvir, dasabuvir ± ribavirin for 12 weeks in treatment experienced patients without cirrhosis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 24 weeks in re-treated cirrhotic individuals
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/daclatasvir for 24 weeks in re-treated cirrhotic individuals
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/simeprevir/1200 mg/d ribavirin for 12 weeks in re-treated cirrhotic individuals
Number of subjects: 18
Study: 25531033

Group type: EXPERIMENTAL
Intervention: Angelica keiskei Koidzumi (AKE) supplementation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82